Cleavable scFv-Transferrin Fusion for Brain Antibody Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies face low bioavailability in the brain due to the restrictive nature of the blood-brain barrier, limiting their therapeutic efficacy in treating neurodegenerative disorders, despite efforts to enhance delivery methods like receptor-mediated transcytosis and chemical disruption, which often result in insufficient brain concentrations and non-selective exposure.
Innovation Solution
Development of a single-chain variable fragment (scFv) fusion protein (RNAT01) that binds specifically to cerebral proteins like amyloid beta, tau, and alpha-synuclein, utilizing transferrin conjugation with engineered linkers to facilitate targeted delivery across the blood-brain barrier through receptor-mediated transcytosis, ensuring optimal binding and controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are administered systemically to treat CNS disorders, then therapeutic activity is provided, but brain penetration is insufficient due to the restrictive blood-brain barrier
Solution Approach 1:
The patent uses transferrin as an intermediary carrier protein that facilitates antibody transport across the blood-brain barrier. The transferrin-antibody fusion protein exploits the transferrin receptor-mediated transcytosis pathway, where transferrin binds to its receptor on endothelial cells, allowing the attached antibody to be transported into the brain parenchyma, thus solving the barrier penetration problem while maintaining therapeutic activity
Solution Approach 2:
The patent modifies the molecular parameters of the antibody by creating a fusion protein with transferrin, changing the size, charge, and surface properties of the therapeutic agent. This parameter change enables the antibody to utilize the transferrin receptor pathway for brain penetration, transforming it from a molecule that cannot cross the BBB to one that can do so efficiently
2Quantity of substance
If the blood-brain barrier is disrupted to improve drug delivery, then brain exposure increases, but non-selective exposure to harmful substances occurs
Solution Approach 1:
The transferrin-antibody fusion protein uses the transferrin receptor as a selective intermediary that naturally transports molecules into the brain. This receptor-mediated pathway provides selectivity, allowing only the attached therapeutic antibody to be transported while blocking harmful substances, thus avoiding the non-selective exposure problem associated with direct BBB disruption methods
Solution Approach 2:
The fusion protein exploits the brain's own transferrin receptor system to facilitate its entry, using the brain's natural transport mechanisms rather than forcing entry through disruption. The transferrin component binds to the receptor and triggers the natural transcytosis process, allowing the antibody to be delivered selectively without compromising the blood-brain barrier's protective function
3Productivity
If bispecific antibodies are used to enhance brain penetration through receptor-mediated transcytosis, then transport efficiency improves, but complexity and manufacturing cost increase significantly
Solution Approach 1:
The patent merges the transferrin carrier protein with the therapeutic antibody in a single fusion protein construct. This combining approach simplifies the structure compared to bispecific antibodies by using a single-chain variable fragment (scFv) domain rather than requiring two separate antibody chains with different specificities, thus reducing manufacturing complexity while maintaining transport efficiency
Solution Approach 2:
The patent segments the antibody structure by using a single-chain variable fragment (scFv) instead of a full bispecific antibody. The scFv contains only the essential variable regions for target binding, separated from the constant regions, and is fused to transferrin. This segmentation reduces the overall complexity and manufacturing difficulty while preserving the necessary transport and therapeutic functions
4Reliability
If full monoclonal antibodies are used, then therapeutic activity is maintained, but bioavailability in the brain remains below 0.1% after peripheral administration
Solution Approach 1:
The patent extracts the essential therapeutic function from the full monoclonal antibody by using a single-chain variable fragment (scFv) that retains the antigen-binding capability. This extraction removes the Fc region and constant regions that hinder BBB penetration, keeping only the variable regions necessary for target engagement, thus dramatically improving bioavailability while maintaining therapeutic activity
Solution Approach 2:
The patent changes the molecular parameters of the antibody by reducing it to a scFv fragment and fusing it with transferrin. This parameter change reduces the molecular size and modifies the surface properties, enabling the antibody fragment to cross the blood-brain barrier efficiently while the transferrin component provides the necessary transport mechanism, thereby increasing bioavailability from below 0.1% to significantly higher levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the bioavailability and therapeutic efficacy of antibodies in the brain by improving their ability to cross the blood-brain barrier, maintaining stability and specificity while avoiding interference with endogenous processes, thereby addressing the low bioavailability challenge.
Implementation Method 1
Macromolecules such as monoclonal antibodies (''mAbs'') can utilize three types of vesicles to traverse brain endothelial cells: (i) clathrin-coated vesicles, (ii) caveolae domains generated from lipid rafts, and (iii) macropinocytotic vesicle. For transcytosis of large molecules, which primarily uses clathrin-coated vesicles, a receiver is required for uptake and trafficking across the brain endothelial cells. This process has been termed 'receptor-mediated transcytosis' (''RMT'').
Implementation Method 2
Development of a single-chain variable fragment (scFv) fusion protein (RNAT01) that binds specifically to cerebral proteins like amyloid beta, tau, and alpha-synuclein, utilizing transferrin conjugation with engineered linkers to facilitate targeted delivery across the blood-brain barrier through receiver-mediated transcytosis, ensuring optimal binding and controlled release.
Data Source
AI summary
Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.